BH_NonClinical_Pharmacy_Car-T
- Barts Health NHS Trust
Procurement identifier (OCID): ocds-h6vhtk-05e8d3
Description
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient's T cells are genetically modified to target cancer cells.
The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products
At the time of writing it is only offered at 8 sites across the UK.
The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order.
The price paid to the supplier with be capped at NICE / NHS England approved list prices.
Notices
UK5: Transparency notice
- Notice identifier
- 2025/S 000-077086
- Published
- 26 November 2025, 9:46am